The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Biogen Idec Inc

Nasdaq: BIIB
Last

(U.S.) $304.92

Today's change-0.48 -0.16%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.
 

Biogen Idec Inc

Nasdaq: BIIB
Last

(U.S.) $304.92

Today's change-0.48 -0.16%
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Biogen Idec Inc down (U.S.)$0.48

Biogen Idec Inc closed lower Wednesday, dropping (U.S.)$0.48 or 0.16% to (U.S.)$304.92. Over the last five days, shares have gained 0.43% and 9.07% year to date. Shares have underperformed the S&P 500 by 9.55% during the last year.

Key company metrics

  • Open(U.S.) $305.00
  • Previous close(U.S.) $305.40
  • High(U.S.) $305.83
  • Low(U.S.) $301.39
  • Bid / Ask-- / --
  • YTD % change+9.07%
  • Volume1,085,880
  • Average volume (10-day)1,669,502
  • Average volume (1-month)1,408,421
  • Average volume (3-month)1,379,112
  • 52-week range(U.S.) $270.27 to (U.S.) $358.89
  • Beta1.12
  • Trailing P/E28.86×
  • P/E 1 year forward22.60×
  • Forward PEG1.03×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $10.57
Updated November 26 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+28.09%

Based on its net profit margin of 28.09%, Biogen Idec Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue2,5112,4212,1301,966
Total other revenue--------
Total revenue2,5112,4212,1301,966
Gross profit2,2092,1301,8511,707
Total cost of revenue303292279259
Total operating expense1,3591,4331,4581,309
Selling / general / administrative570577512523
Research & development417447529422
Depreciation / amortization122117143109
Interest expense (income), net operating--------
Unusual expense (income)-540-5-4
Other operating expenses, total0000
Operating income1,153989671657
Interest income (expense), net non-operating-7-7-8-6
Gain (loss) on sale of assets--------
Other--------
Income before tax1,136994666653
Income after tax862725487462
Income tax, total275269178190
Net income857715480457
Total adjustments to net income--------
Net income before extra. items857715480457
Minority interest1-900
Equity in affiliates-5-2-8-5
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items857715480457
Inc. avail. to common incl. extra. items857715480457
Diluted net income857715480457
Dilution adjustment--------
Diluted weighted average shares237237238238
Diluted EPS excluding extraordinary itemsvalue per share3.623.012.021.92
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share3.443.012.001.91